Paid Clinical Trials and Focus Groups by Category |
|
|
|
Conditions: Castrate-Resistant Prostate Cancer; Hormone Refractory Prostate Cancer
Interventions: Drug: custirsen sodium; Drug: Isotonic, 0.9% sodium chloride
Sponsors: OncoGenex Technologies; Teva Pharmaceuticals USA
Not yet recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Drug: HDAC inhibitor SB939; Other: laboratory biomarker analysis
Sponsor: NCIC Clinical Trials Group
Recruiting - verified February 2010
Condition: Castration-Resistant Prostate Cancer
Interventions: Drug: MDV3100; Drug: Placebo
Sponsor: Medivation, Inc.
Recruiting - verified March 2010
Conditions: Colorectal Neoplasms; Lung Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Sarcoma
Interventions: Drug: figitumumab; Drug: pegvisomant
Sponsor: Pfizer
Recruiting - verified March 2010
Conditions: Cancer; Cataract; Low Bone Mineral Density; Osteopenia; Osteoporosis; Prostate Cancer
Interventions: Biological: Denosumab; Biological: Placebo
Sponsor: Amgen
Recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Drug: Ipilimumab; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified January 2010
Conditions: Cancer; Carcinoma; Castrate-Resistant Prostate Cancer; Prostate Cancer; Tumors
Intervention: Drug: Denosumab
Sponsor: Amgen
Recruiting - verified March 2010
Condition: Recurrent Prostate Cancer
Intervention: Device: High Intensity Focused Ultrasound
Sponsor: USHIFU, LLC
Recruiting - verified March 2010
Condition: Prostatic Neoplasms
Intervention:
Sponsors: University of Washington; Canary Foundation; Early Detection Research Network
Recruiting - verified February 2010
Condition: Prostatic Neoplasms
Interventions: Drug: placebo + docetaxel/prednisone; Drug: dasatinib + docetaxel/prednisone
Sponsor: Bristol-Myers Squibb
Recruiting - verified October 2009
Conditions: Hormone Refractory Prostate Cancer; Bone Metastases
Interventions: Drug: Alpharadin (Radium-223); Drug: Placebo
Sponsor: Algeta ASA
Recruiting - verified March 2009
Condition: Prostatic Neoplasms
Interventions: Drug: Prednisone; Drug: sunitinib; Drug: Placebo; Drug: Prednisone
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Drug: ZD4054; Drug: Luteinising hormone-releasing hormone analogue (LHRHa); Drug: Megace; Drug: Estradiol; Drug: Prednisolone; Drug: Ketoconazole; Drug: Docetaxel
Sponsor: AstraZeneca
Recruiting - verified February 2010
Condition: Prostate Cancer
Interventions: Drug: Docetaxel; Drug: ZD4054
Sponsor: AstraZeneca
Recruiting - verified February 2010
Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: flutamide; Radiation: radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI); Cancer and Leukemia Group B
Recruiting - verified March 2010
Condition: Prostate Cancer
Intervention: Device: Sonablate 500 (SB-500)
Sponsor: USHIFU, LLC
Not yet recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Other: active surveillance; Procedure: conventional surgery; Procedure: quality-of-life assessment; Radiation: brachytherapy; Radiation: radiation therapy
Sponsors: NCIC Clinical Trials Group; National Cancer Institute (NCI); Cancer and Leukemia Group B; Eastern Cooperative Oncology Group; Southwest Oncology Group
Recruiting - verified March 2010
Condition: Neoplasms
Interventions: Drug: OGX-427; Drug: Docetaxel
Sponsor: OncoGenex Technologies
Recruiting - verified February 2010
Condition: Prostate Cancer
Interventions: Drug: docetaxel; Drug: goserelin; Drug: leuprolide acetate; Procedure: conventional surgery
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; NCIC Clinical Trials Group
Recruiting - verified March 2010
Conditions: Breast Cancer; Cognitive/Functional Effects; Lung Cancer; Metastatic Cancer; Prostate Cancer
Interventions: Radiation: radiation therapy; Radiation: stereotactic radiosurgery
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI); American College of Surgeons; Eastern Cooperative Oncology Group; Radiation Therapy Oncology Group
Recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Procedure: 7800 cGy/39 fractions in 8 weeks; Procedure: 6000 cGy/20 fractions in 4 weeks
Sponsors: Ontario Clinical Oncology Group (OCOG); Canadian Institutes of Health Research (CIHR); Trans-Tasman Radiation Oncology Group (TROG)
Recruiting - verified February 2010
Condition: Prostate Cancer
Intervention: Device: Integrated Imaging High Intensity Focused Ultrasound
Sponsor: EDAP TMS S.A.
Recruiting - verified February 2010
Conditions: Metastatic Cancer; Prostate Cancer
Interventions: Drug: zoledronic acid; Other: placebo
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI); Southwest Oncology Group; Eastern Cooperative Oncology Group; NCIC Clinical Trials Group
Recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Radiation: iodine I 125; Radiation: palladium Pd 103; Radiation: radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
All Categories ... by Medical Condition » ... Benign Prostate (BPH) » ... Canada 
Login/sign up for more tools for finding clinical trials. Login/Sign up Here
